Cyklokapron, also known as Tranexamic Acid, contains the active ingredient tranexamic acid. This medication is used to help reduce bleeding by preventing blood clots from breaking down too quickly. It is often prescribed for heavy menstrual bleeding and surgeries where excessive blood loss is a risk.
The cost of the Cyklokapron varies from £1.67 to £2.71 per pills. It depends on the pack size and the amount of active ingredient (30 or 270 mg).
Cyklokapron, also known as tranexamic acid, is typically administered orally. The recommended dosage for adults is 1,000 mg taken 2-3 times daily, usually for up to 5 days. For specific indications like menorrhagia, the regimen may vary, and ongoing medical oversight is essential to tailor the dosage to individual needs.
In cases where intravenous administration is necessary, such as during surgical procedures, the initial dose is usually 10 mg/kg intravenously. The dose may be repeated every 6-8 hours, depending on the clinical scenario and patient response. Adjustments are often based on factors like the nature of the surgery and the patient’s bleeding risk.
Tranexamic acid, the active ingredient in Cyklokapron, is a synthetic derivative of the amino acid lysine. It works by inhibiting fibrinolysis, which is the process that breaks down blood clots. By blocking the formation of plasmin from plasminogen, it stabilizes clots and reduces excessive bleeding.
This mechanism is crucial in conditions where inappropriate clot breakdown causes hemorrhage, such as during surgeries or in individuals with hereditary bleeding disorders. The stabilization effect is time-sensitive, making timely administration vital for efficacy.
Cyklokapron exhibits high bioavailability when taken orally, with up to 50% of the administered dose absorbed in the gastrointestinal tract. Peak plasma concentrations are achieved within 2-3 hours post-ingestion. The drug is not significantly metabolized and is primarily excreted unchanged in the urine.
The elimination half-life of tranexamic acid is approximately 2 hours, which underscores the need for repeated dosing to maintain therapeutic levels. Renal excretion emphasizes caution in patients with renal impairment, necessitating dosage adjustments to prevent accumulation and toxicity.
Cyklokapron is indicated for the prevention and treatment of hemorrhages associated with excessive fibrinolysis. Specific conditions include heavy menstrual bleeding, hereditary angioedema, and bleeding complications during surgeries such as dental procedures in hemophiliac patients.
The efficacy of tranexamic acid in trauma care is also recognized, where it is used to mitigate bleeding and improve survival rates. Its role extends to reducing postoperative bleeding and the need for blood transfusions in cardiac and orthopedic surgeries.
The use of Cyklokapron is contraindicated in patients with active thromboembolic disease, where the risk of clot formation is already elevated. This includes conditions such as deep vein thrombosis, pulmonary embolism, and cerebral thrombosis.
Individuals with a known hypersensitivity to tranexamic acid or any of its excipients should not use this medication. Additionally, patients with acquired defective color vision should avoid Cyklokapron, as it can exacerbate this condition.
Gastrointestinal disturbances such as nausea, vomiting, and diarrhea are among the most frequently reported side effects. These symptoms are generally mild to moderate in severity and tend to resolve with continued use or dosage adjustments.
Neurological effects including headache, dizziness, and visual disturbances have been observed. These effects are usually transient but warrant monitoring and, if persistent, may necessitate medical intervention or discontinuation of the drug.
Cyklokapron may interact with other medications that affect blood clotting. Concomitant use with anticoagulants like warfarin or heparin can counteract the drug’s effect and increase the risk of bleeding complications. Regular monitoring of coagulation parameters is recommended when such combinations are necessary.
Nonsteroidal anti-inflammatory drugs (NSAIDs) can potentiate the risk of adverse effects on the gastrointestinal tract. Combined use should be approached with caution, and patients should be advised on signs of gastrointestinal bleeding.
Before initiating therapy, a thorough medical history, including any previous thrombotic events, hypersensitivity reactions, and current medications, should be obtained. Patients with renal impairment require special attention, with dosage modifications and periodic renal function assessments to prevent drug accumulation and potential toxicity.
Regular monitoring of blood coagulation parameters is vital during prolonged treatment, especially in patients undergoing surgery or those with complex bleeding disorders. Adherence to treatment guidelines is critical to minimize risks and optimize clinical outcomes.
Advise patients on the importance of adhering to the prescribed dosage regimen and not exceeding the recommended administration duration. Educate them on recognizing adverse effects, particularly signs of thrombotic events, severe gastrointestinal disturbances, and hypersensitivity reactions.
Patients should be instructed to report any unusual symptoms or worsening of their condition promptly. Emphasize the significance of regular medical follow-ups and laboratory tests to monitor their response to therapy and detect any potential complications early.